Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream

Université Laval

$100,000.00

What are the implications of Anti-HIV drugs interaction with Transporters proteins in: Anatomical Viral reservoirs persistence, cytotoxicity and co-infection?

EF 2009-10

Résumé
Highly Active Anti-Retroviral Therapy (HAART) has achieved high-level suppression of viral load in HIV-1-infected patients. The idea behind the HAART is to bloc different steps in the viral cycle by using combination of different antiviral drug classes. Unfortunately, the emergence of drug resistance frequently occurs because of rapid mutation of viral genome. In addition, it is assumed that host cellular factors are also involved in the resistance to antiretroviral drugs. One factor that may limit the therapeutic efficacy of anti-HIV drugs is the multidrug transporters. These transporter proteins are known to interact with several classes of antiviral drugs and were directly linked to low accumulation of some anti-retroviral drugs. Consequently, decreasing the cellular drugs levels at these sites could lead to an inability to suppress viral replication and contribute to development of drug resistance and to the failure of anti-retroviral therapy. Furthermore, the adverse drug reactions in a significant proportion of patients are a direct consequence of anti-HIV drug clearance mediated by transporters proteins. The overall aim of this project is to identify the key structural features, and thus mechanisms, by which these multidrug transporters recognize and transport anti-HIV drugs. The results of these studies have the potential to provide important information to guide for drug development efforts to design an inhibitor capable of overcoming drug resistance observed in clinic.
Programme
Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
199385
Name
Haimeur Anass
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
What are the implications of Anti-HIV drugs interaction with Transporters proteins in: Anatomical Viral reservoirs persistence, cytotoxicity and co-infection?
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: HIV/AIDS Bridge Funding - Biomedical/Clinical Stream
Keyworddelim
Abc Transporters; Anti-Hiv Drug And Protein Interactions; Anti-Hiv Drug Clearance; Hiv/Aids; Photo-Affinity Labeling; Protein Engineering
Abstract
Highly Active Anti-Retroviral Therapy (HAART) has achieved high-level suppression of viral load in HIV-1-infected patients. The idea behind the HAART is to bloc different steps in the viral cycle by using combination of different antiviral drug classes. Unfortunately, the emergence of drug resistance frequently occurs because of rapid mutation of viral genome. In addition, it is assumed that host cellular factors are also involved in the resistance to antiretroviral drugs. One factor that may limit the therapeutic efficacy of anti-HIV drugs is the multidrug transporters. These transporter proteins are known to interact with several classes of antiviral drugs and were directly linked to low accumulation of some anti-retroviral drugs. Consequently, decreasing the cellular drugs levels at these sites could lead to an inability to suppress viral replication and contribute to development of drug resistance and to the failure of anti-retroviral therapy. Furthermore, the adverse drug reactions in a significant proportion of patients are a direct consequence of anti-HIV drug clearance mediated by transporters proteins. The overall aim of this project is to identify the key structural features, and thus mechanisms, by which these multidrug transporters recognize and transport anti-HIV drugs. The results of these studies have the potential to provide important information to guide for drug development efforts to design an inhibitor capable of overcoming drug resistance observed in clinic.
Competitiondate
200909
Approvedterm2
1 yr 0 mth
Pinamesdelim
Haimeur, Anass
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~